

1 **Short-term outcomes associated with temozolomide vs. PCV chemotherapy for 1p/19q-**
2 **codeleted WHO grade III anaplastic oligodendrogliomas: a national evaluation**

3
4 Nayan Lamba, M.D.^{1,2}; Malia McAvoy, M.S.^{3,4}; Vasileios K. Kavouridis, M.D., M.P.H.^{4,5}; Timothy R.
5 Smith, M.D., Ph.D., M.P.H.^{3,4}; Mehdi Touat, M.D.^{6,7}; David A. Reardon, M.D.^{3,8}; J. Bryan Iorgulescu,
6 M.D.^{3,4,9,10}

7
8 ¹Department of Radiation Oncology, Brigham and Women's Hospital, Boston, MA

9 ²Department of Medicine, Cambridge Health Alliance, Cambridge, MA

10 ³Harvard Medical School, Boston, MA

11 ⁴Computational Neuroscience Outcomes Center, Department of Neurosurgery, Brigham and Women's
12 Hospital, Boston, MA

13 ⁵Department of Surgery, St. Elizabeth's Medical Center, Brighton, MA

14 ⁶Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA

15 ⁷Sorbonne Université; Institut du Cerveau et de la Moelle épinière; Service de Neurologie, Hôpitaux
16 Universitaires La Pitié Salpêtrière, Paris, France

17 ⁸Center for Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Center, Boston, MA

18 ⁹Department of Pathology, Brigham and Women's Hospital, Boston, MA

19 ¹⁰Department of Medical Oncology, Dana-Farber Cancer Institute, Boston MA

20
21 **Running head:** TMZ vs PCV for WHO grade III Oligodendroglioma

22
23 **Corresponding author:**

24 J. Bryan Iorgulescu, M.D.

25 Department of Pathology, Brigham and Women's Hospital

26 Department of Medical Oncology, Dana-Farber Cancer Institute

27 Harvard Medical School

28 75 Francis St., Boston, MA 02115

29 Phone: 617-732-7510, Fax: 617-277-9015

30 jiorgulescu@bwh.harvard.edu

31
32 This work was presented in part at the 2019 annual meeting of the Society for Neuro-Oncology.

36 **Abstract**

37 **PURPOSE:** The optimal chemotherapy regimen between temozolomide (TMZ) and procarbazine,
38 lomustine, and vincristine (PCV) remains uncertain for newly-diagnosed anaplastic oligodendroglioma
39 (AO). We therefore addressed this question using a national database.

40 **METHODS:** Patients newly-diagnosed with 1p/19q-codeleted W.H.O. grade III AO between 2010-
41 2016 were identified from the National Cancer Database. Predictors of receiving first-line single-agent
42 TMZ vs. multi-agent PCV were assessed by multivariable logistic regression. Overall survival (OS) was
43 estimated by Kaplan-Meier techniques and evaluated by multivariable Cox regression.

44 **RESULTS:** 1,360 AO patients were identified: 74.5% (n=1,013) treated with TMZ, 9.6% (n=131) with
45 PCV, and 15.9% (n=216) with no chemotherapy in the first-line setting. In multivariable logistic analysis,
46 PCV utilization increased from 2010 to 2016 (OR=1.38/year, 95%CI: 1.22-1.56, p<0.001) and was less
47 commonly utilized in privately insured patients (OR=0.38 vs. uninsured, 95%CI: 0.15-0.97, p=0.04). In
48 survival analyses (33.1% reached endpoint), there was no difference in unadjusted OS between TMZ
49 (5yr-OS 60.1%, 95%CI: 55.9-64.1) and PCV (5yr-OS 61.1%, 95%CI: 45.6-73.5; p=0.42). There
50 remained no OS difference between TMZ and PCV in the 75.9% (n=1,032) of AO patients that also
51 received radiotherapy (p=0.51), in the Cox regression analysis adjusted by age, extent of resection, and
52 radiotherapy (TMZ vs. PCV HR=1.31, 95%CI: 0.83-2.08, p=0.24), and in subgroup analyses that
53 incorporate KPS or *MGMT* status.

54 **CONCLUSIONS:** In a national database of AOs managed in the ‘real-world’ setting, there is no
55 difference in the short-term mortality between first-line TMZ and PCV chemotherapy. These findings
56 provide preliminary data while we await the long-term results from the CODEL trial.

57

58 **Key Words:** Anaplastic oligodendroglioma, Chemotherapy, Temozolomide, PCV

59 **Declarations:** The authors have no declarations.

60 **Funding:** JBI is supported by an NIH 5T32HL007627 award.

61 **Conflicts of interest:** The authors report no conflicts of interest.

62 **Availability of data and material:** Data are publicly available by application to the American College of
63 Surgeons in accordance with the National Cancer Database's data use agreement.

64 **Code availability:** Available upon request.

65 **Authors' contributions:** Conception and study design: JBI. Data collection: NL, MM, VK. Data
66 analysis: JBI. Data interpretation and Manuscript writing: All authors. Critical review and revisions: All
67 authors.

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85 **Introduction**

86 Diffuse gliomas are a common primary intracranial tumor associated with significant morbidity
87 and mortality.¹ W.H.O. grade III anaplastic oligodendrogliomas (AOs) are a rare subset of diffuse
88 gliomas, comprising about 6% of all gliomas, and, per the 2016 W.H.O. classification, are defined by the
89 presence of both an *IDH* mutation and 1p/19q chromosomal codeletion.² The 1p/19q chromosomal
90 codeletion is a strong prognostic marker associated with increased responsiveness to chemotherapy and
91 superior outcomes in patients with diffuse gliomas.^{3,4} However, despite recent advances in understanding
92 its distinct molecular profile, the optimal therapeutic regimen for newly-diagnosed AOs remains unclear
93 and controversial.⁵

94 The NCCN guidelines (version 3.2019) currently recommend maximal safe surgical resection
95 followed by radiotherapy (RT) and chemotherapy for AOs.^{4,6} The addition of chemotherapy to RT in
96 patients with AO stems from two major randomized controlled trials that demonstrated improved survival
97 among patients harboring a 1p/19q-codeletion who received procarbazine, lomustine, and
98 vincristine (PCV) chemotherapy with RT, as compared to those who received RT alone.^{7,8} More recently,
99 in light of the results of the EORTC 26981–22981/NCIC CE3 trial, as well as evidence demonstrating
100 that temozolomide (TMZ) may have a lower toxicity profile and more convenient administration than
101 PCV, there has been interest in assessing whether TMZ might replace PCV in the treatment of AOs.⁴ The
102 CODEL trial (NCT00887146), which presently randomizes newly-diagnosed oligodendroglioma patients
103 to RT with either adjuvant PCV or with concomitant TMZ (followed by adjuvant TMZ), is expected to
104 answer this question in the future;⁹ however, until its results become available, there is no clear consensus
105 among the neuro-oncology community as to which regimen to use in the management of patients with
106 AOs.⁵

107 Given the concerns surrounding PCV-related toxicity, we sought to compare outcomes for newly-
108 diagnosed AO patients following TMZ or PCV in the first-line setting using a large national cancer
109 database. As the results of the CODEL trial are years away, our study has the potential to offer clinical
110 guidance about the efficacy of these regimens in the management of patients with newly-diagnosed AO.

111

112 **Materials and Methods**

113 *Data Source and Study Design*

114 The National Cancer Database (NCDB) is a nationwide database comprising more than 70% of
115 newly diagnosed cancers in the United States.¹⁰ Patients were identified with histologically-confirmed
116 newly-diagnosed diffuse gliomas between 2010 (1p/19q codeletion data are only incorporated in the
117 NCDB as of 2010) and 2016, as defined by the ICD-O-3 histological codes (*i.e.* 9380-9382, 9400-9401,
118 9420, 9440-9442, 9450-9451, and 9460), a malignant behavior code (*i.e.* 3), and any brain site code (*i.e.*
119 71.0-71.9).¹¹ Anaplastic oligodendrogliomas were defined herein using the primary brain-specific
120 variables for W.H.O. grade III and for loss of heterozygosity/deletion of both chromosome arms 1p and
121 19q.¹² A subset of cases with 1p/19q-codeletion were encoded in the NCDB as W.H.O. grade IV – likely
122 reflecting the outmoded “glioblastoma with oligodendroglial features” – and herein were reclassified as
123 W.H.O. grade III AOs in accordance with the revised 2016 W.H.O. classification. Patients were excluded
124 if they had a prior diagnosis of cancer (thereby excluding W.H.O. grade II oligodendrogliomas that
125 subsequently transformed into AO), were <20-years-old at diagnosis, were diagnosed at an index
126 institution and treated entirely elsewhere, or if they were not 1p/19q-codeleted. Patients were also
127 excluded if they lacked complete data regarding receipt of chemotherapy or RT.

128

129 *Variables and Statistical Analyses*

130 Chemotherapy is encoded in the NCDB as single-agent or multi-agent, without further details. In
131 order to confirm that single-agent referred to temozolomide and multi-agent to PCV, we reviewed all
132 encoded chemotherapy data for AOs from registry-submitted data from two cancer centers (Brigham and
133 Women’s Hospital/Dana-Farber Cancer Center and Massachusetts General Hospital) and validated their
134 encoding using the medical records. Associations between clinicopathologic factors, including age at
135 diagnosis, sex, race/ethnicity, Charlson-Deyo comorbidity index, year of diagnosis, insurance status,
136 hospital type and location, tumor size (greatest dimension), extent of resection (EOR), and receipt of

137 single-agent vs. multi-agent chemotherapy were assessed with multivariable logistic regression. Brain-
138 specific EOR was stratified as biopsy-only, subtotal resection, or gross total resection. *IDH* mutation
139 status is not encoded in the NCDB.

140 As previously described, overall survival (OS) was measured from the date of AO diagnosis to
141 the date of death, with patients censored at the date of most recent follow-up.^{12,13} OS was estimated by
142 Kaplan-Meier methods and compared by log-rank tests and Cox regression analysis. Multivariable Cox
143 proportional hazards regression was used to evaluate the association between chemotherapy regimen and
144 OS. Due to limited follow-up, the NCDB excludes OS data for patients diagnosed in the final year of the
145 dataset, which for this dataset was 2016 – therefore AO patients diagnosed in 2016 are excluded from
146 survival analyses. Because Karnofsky performance status (KPS, stratified as ≤ 60 vs. >60) and *MGMT*
147 promoter methylation status were only encoded in a minority of patients (17.2% and 32.5% herein,
148 respectively), these variables were separately added to the multivariable Cox regression analysis as
149 subgroup analyses. STATA (v. 14.2, StataCorp) was used for statistical analyses, with 2-sided p-values
150 <0.05 specified as significant. This study was approved by the Partners HealthCare institutional review
151 board (#2015P002352).

152

153 **Results**

154 1,360 U.S. patients with newly-diagnosed 1p/19q-codeleted W.H.O. grade III AOs were
155 identified; of whom 74.5% (n=1,013) received single-agent chemotherapy, 9.6% (n=131) received multi-
156 agent chemotherapy, and 15.9% (n=216) had no chemotherapy in the first-line setting. From two of the
157 NCDB's institutions, 73 1p/19q-codeleted AOs treated with chemotherapy between 2000-2017 were
158 encoded and submitted to registries. Of these, 84.9% (n=62) and 15.1% (n=11) were encoded as first-line
159 single-agent and multi-agent chemotherapy and were validated by medical chart review to represent TMZ
160 and PCV, respectively, in all cases.

161 In multivariable logistic analysis of the national sample, privately insured patients were
162 significantly less likely to receive multi-agent PCV (odds ratio [OR] 0.38, 95% confidence interval [CI]:

163 0.15-0.97, $p=0.04$) than uninsured patients (Table 1). AOs that were more recently diagnosed, however,
164 were significantly associated with increased utilization of PCV (OR 1.38/year, 95%CI: 1.22-1.56,
165 $p<0.001$). Receipt of single-agent TMZ vs. multi-agent PCV chemotherapy was otherwise independent of
166 AO patients' sex, age, race/ethnicity, comorbidity index, EOR, RT, tumor size (greatest dimension),
167 hospital type, or hospital geographic location (all $p>0.05$, Table 1). 75.9% ($n=1,032$) of AO patients also
168 received RT (42.7% as 60 Gy and 33.2% as 59.4 Gy). RT began a median of 36 days (interquartile range
169 [IQR] 28-47) after definitive resection; and single-agent TMZ chemotherapy often began on the same day
170 as RT (median difference 0 days, IQR: 0-0), whereas multi-agent PCV chemotherapy often began
171 following RT (median difference 64 days, IQR: 0-78.5; t-test $p<0.001$).

172 In terms of OS, the median follow-up was 27.7 months (interquartile range [IQR] 12.4-49.9
173 months) with 33.1% of patients reaching the endpoint of mortality in the national sample. Unadjusted OS
174 estimates were not significantly different between single-agent TMZ (5yr-OS 60.1%, 95%CI: 55.9-64.1)
175 and multi-agent PCV chemotherapy (5yr-OS 61.1%, 95%CI: 45.6-73.5; Cox regression $p=0.42$), but both
176 were significantly better than no chemotherapy (5yr-OS 46.5%, 95%CI: 36.8-55.7, $p\leq 0.001$; Fig. 1). In
177 the 1,032 patients who also had RT, there remained no significant OS difference between TMZ (5yr-OS
178 56.1%, 95%CI: 51.4-60.6) and PCV (5yr-OS 54.0%, 95%CI: 36.0-68.9, $p=0.51$). In the 15.9% of AO
179 patients who did not receive chemotherapy, 53.5% had resection alone, 19.8% had resection with RT, and
180 4.8% had biopsy with RT.

181 In multivariable Cox regression analysis adjusted for age, EOR, and RT – factors previously
182 shown to have prognostic value in AOs – there was no difference in OS between first-line TMZ (HR 1.31,
183 95%CI: 0.83-2.08, $p=0.24$) and PCV chemotherapy, and either regimen significantly improved OS
184 compared to no chemotherapy (Table 2). The lack of an OS difference persisted in subgroup analyses that
185 incorporated KPS ($n=188$, TMZ HR 0.92 vs. PCV, 95%CI: 0.12-6.94, $p=0.94$) and *MGMT* promoter
186 methylation status ($n=265$, TMZ HR 1.04 vs. PCV, 95%CI: 0.50-2.16, $p=0.91$).

187

188 **Discussion**

189 In this national analysis of 1,360 patients with newly-diagnosed 1p/19q-codeleted W.H.O. grade
190 III anaplastic oligodendroglioma, we found no significant difference in short-term OS between patients
191 treated with first-line single-agent (TMZ-based) vs. multi-agent (PCV-based) chemotherapy regimens.
192 These findings persisted after adjusting for key prognostic variables of age at diagnosis, EOR, and RT,
193 together providing support for the similarity of short-term OS outcomes for first-line TMZ vs. PCV in this
194 patient population.

195 Two landmark trials established the chemosensitivity of 1p/19q-codeleted oligodendrogliomas
196 and defined a role for PCV in the treatment of AOs: Radiation Therapy Oncology Group (RTOG) 9402
197 and the European Organization for Research and Treatment of Cancer (EORTC) 26951 both showed that
198 among patients with 1p/19q-codeleted tumors, treatment with RT and PCV resulted in significant
199 improvements in OS as compared to treatment with adjuvant RT alone.^{7,8} However, despite the
200 compelling evidence in favor of adjuvant PCV, its use in clinical practice has been limited by its
201 significant toxicity.¹⁴ Specifically, lomustine can cause bone marrow suppression and procarbazine can
202 result in intractable nausea and skin reactions that require its discontinuation. In addition, vincristine is
203 not thought to achieve appreciable penetration of the blood-brain-barrier, potentially limiting the overall
204 efficacy of PCV in the treatment of an intracranial tumor.¹⁵ In light of patients' poor tolerance of and
205 ability to complete treatment with PCV, TMZ has also been explored as a potential alternative in the
206 treatment of AOs.

207 Numerous retrospective studies have demonstrated that TMZ may be a safe and efficacious
208 alternative for AO treatment, achieving similar response rates as chemotherapy with PCV. In a clinical
209 efficacy trial of 20 patients with AO, TMZ was given for up to 24 weeks following surgical resection:
210 results demonstrated a high response to TMZ, with clinical improvement reported in 60% of patients and
211 only two reports of grade 3/4 toxicity.¹⁶ Similarly, another phase II study assessed the use of upfront TMZ
212 in the treatment of newly-diagnosed AO and found a median progression-free survival (PFS) of 62
213 months, with limited high-grade toxicities despite a dose-intense schedule.¹⁷ Robust tumor responsiveness
214 and well-managed toxicity following TMZ for AO have been consistently observed in retrospective

215 studies.^{18,19} It should be noted, however, that none of the above studies included RT, so it is possible that
216 response rates might have been even higher had RT been added to TMZ therapy, although toxicity
217 profiles may also have been more severe.

218 Despite these reports suggesting an opportunity for TMZ in first-line treatment of AO, whether
219 TMZ can outperform PCV remains uncertain. There have been a limited number of retrospective studies
220 that have attempted to compare these two chemotherapy regimens head-to-head; ever fewer of which
221 have incorporated the 2016 revised W.H.O. histomolecular definitions of AOs. In a large multi-
222 institutional retrospective study by Lassman *et al.*, in which only 89 1p/19q-codeleted AOs were
223 compared by chemotherapy agent, PCV-alone demonstrated improved time-to-progression (median 7.6
224 months compared to 3.3 months in TMZ-alone, $p=0.02$), but no difference in OS ($p=0.16$).²⁰ In the AOs
225 that also received RT, there was no difference in either time-to-progression or OS for PCV vs. TMZ.²⁰ In
226 the Neuro-Oncology Working Group (NOA) phase III trial NOA-04, in which patients with anaplastic
227 gliomas (only 69 with 1p/19q-codeletion) were randomized to upfront RT or upfront chemotherapy
228 (either PCV or TMZ), researchers ultimately found that chemotherapy alone was not superior to RT.²¹ In
229 the subset ($n=33$) of CpG island hypermethylated (CIMP) 1p/19q-codeleted cases, PCV-alone
230 demonstrated improved PFS, but not OS, compared to TMZ-alone. Notably, although NOA-04
231 demonstrated better tumor control with PCV, it also demonstrated worse toxicity with PCV. Among the
232 anaplastic glioma patients treated with upfront chemotherapy, treatment was discontinued in 33% of
233 patients treated with PCV ($n=54$), all due to toxicity, while none of the TMZ-treated patients ($n=53$)
234 required TMZ discontinuation due to toxicity.²² Although the Lassman *et al.* study and NOA-04 had
235 moderate follow-up durations of approximately 10 years, it is highly likely that their data had not yet
236 reached maturity and were underpowered with respect to the question of PCV vs. TMZ for AOs. Similar
237 to these studies, our data only capture the short-term outcomes of PCV vs. TMZ for AOs, and it is
238 possible that with much longer follow-up one regimen may prove superior at later landmarks. To
239 rigorously answer this question the phase III CODEL trial (NCT00887146) has been redesigned as a
240 randomized noninferiority comparison of RT either followed by adjuvant PCV or with concomitant TMZ

241 followed by adjuvant TMZ for grade II and III newly-diagnosed 1p/19q-codeleted oligodendrogliomas,
242 powered for PFS, and secondarily assessing OS, toxicity, and quality of life outcomes.

243 Because the final results of CODEL are likely years away, we evaluated the short-term OS
244 outcomes associated with PCV or TMZ as first-line treatment in a contemporary national cohort of 1,360
245 patients with newly-diagnosed 1p/19q-codeleted AOs. Nationally, utilization of TMZ vs. PCV was
246 significantly affected by insurance status: nearly twice as many uninsured AO patients received PCV as
247 privately insured patients – suggesting that insurance-related financial barriers may pose challenges to
248 TMZ access. Although prior work has suggested that TMZ may be surpassing PCV as the regimen-of-
249 choice for gliomas given the favorable toxicity profiles of TMZ,²³ in our analysis utilization of PCV
250 actually increased for AOs from 2010 to 2016. This increase may reflect the timely publication of results
251 from the RTOG 9402 and EORTC 26951 randomized controlled trials, which firmly established the
252 survival benefit of adding PCV to RT for 1p/19q-codeleted gliomas. TMZ vs. PCV rates were otherwise
253 independent of patient age, sex, comorbidity status, tumor size, hospital type and location, RT, and EOR.
254 In line with the studies' survival findings above, we found no difference in short-term OS between AOs
255 treated with first-line PCV versus TMZ. This included in the setting of RT, as well as after multivariable
256 adjustment for age, EOR, RT, *MGMT* promoter methylation status, and/or KPS.

257

258 *Limitations*

259 Although our analysis encompasses a national dataset, the NCDB's limited encoding of 1p/19q-
260 codeletion status only as of 2010 constrained our follow-up to a median of 28 months. As a result, our
261 findings only apply to the short-term outcomes of 1p/19q-codeleted AO patients and do not capture any
262 delayed differences between PCV and TMZ. Based on a two-tailed log-rank power analysis using the
263 Schoenfeld method, this sample set has 90% power to detect a 0.56 HR between the OS of TMZ and
264 PCV. Although only results from a randomized trial comparing PCV and TMZ will be able to ultimately
265 answer this question, our findings suggest that either PCV or TMZ may offer comparable early OS

266 outcomes in the first-line management of newly-diagnosed AOs and support the tailoring of the TMZ vs.
267 PCV selection to each patient's unique circumstances.

268 Even though national registry-based databases like the NCDB provide an unparalleled look at
269 outcomes in a real-life treatment population, they are constricted by several key limitations. First-line
270 chemotherapy is encoded as single-agent and multi-agent, without details about agents, doses, early and
271 late toxicities, or duration of treatment. To help address this limitation, registry-submitted data for AOs
272 from two institutions were evaluated, in which all single-agent cases were TMZ and all multi-agent cases
273 were PCV. Furthermore, only the initial courses of therapy are encoded in the NCDB, so it is possible that
274 some cases received additional single-agent or multi-agent chemotherapy as second-line therapy.
275 Molecular data are also very limited in registry data: 1p/19q-codeletion status was only incorporated as of
276 2010, resulting in a median follow-up for this analysis of 28 months, without details about the diagnostic
277 methodology. *IDH* mutational status is presently lacking in registry data, so all oligodendrogliomas herein
278 were defined by their 1p/19q-codeletion and thus were also likely *IDH* mutant.¹¹ *MGMT* promoter
279 methylation was encoded in a minority of cases, but CpG island hypermethylation data are not included.
280 Additionally, only OS is encoded for outcomes, precluding the evaluation of PFS for PCV vs. TMZ in
281 AOs.

282

283 *Conclusions*

284 In this study of 1,360 patients with newly-diagnosed 1p/19q-codeleted AO, we found no
285 difference in the short-term OS between first-line multi-agent PCV and single-agent TMZ chemotherapy,
286 including in the setting of RT. In addition, we found overall utilization of PCV to be on the rise between
287 2010 and 2016, and that uninsured patients were significantly more likely to receive PCV than privately
288 insured patients – suggesting that there may exist insurance-related financial barriers to the access of
289 TMZ. While results from the CODEL trial will ultimately offer guidance with respect to optimal
290 management for patients with newly-diagnosed AO, our results offer preliminary evidence that both TMZ
291 and PCV chemotherapy regimens may be viable options in the first-line setting.

292

293 **Acknowledgements:** The authors are grateful to the cancer registrars at BWH/DFCI and MGH for their
294 invaluable assistance in data acquisition. JBI acknowledges support by the NIH (T32HL007627).

295

296 **References**

- 297 1. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS Statistical Report: Primary brain and other central
298 nervous system tumors diagnosed in the United States in 2010-2014. *Neuro-Oncol.* 2017.
299 doi:10.1093/neuonc/nox158
- 300 2. Louis DN, Ohgaki H, Cavenee WK. *World Health Organization Histological Classification of*
301 *Tumours of the Central Nervous System.* Vol 1. revised 4th. France: International Agency for
302 Research on Cancer; 2016.
- 303 3. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic
304 response and survival in patients with anaplastic oligodendrogliomas. *J Natl Cancer Inst.* 1998.
305 doi:10.1093/jnci/90.19.1473
- 306 4. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: A clinical review. *JAMA.*
307 2013. doi:10.1001/jama.2013.280319
- 308 5. Ruff MW, Buckner JC, Johnson DR, van den Bent MJ, Geurts M. Neuro-Oncology Clinical Debate:
309 PCV or temozolomide in combination with radiation for newly diagnosed high-grade
310 oligodendroglioma. *Neuro-Oncol Pract.* 2019;6(1):17-21. doi:10.1093/nop/npy044
- 311 6. NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. version 3.2019
312 (November 11,2019) https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf.
- 313 7. Van Den Bent MJ, Brandes AA, Taphoorn MJB, et al. Adjuvant procarbazine, lomustine, and
314 vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up
315 of EORTC brain tumor group study 26951. *J Clin Oncol.* 2013. doi:10.1200/JCO.2012.43.2229
- 316 8. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic
317 oligodendroglioma: Long-term results of RTOG 9402. *J Clin Oncol.* 2013.
318 doi:10.1200/JCO.2012.43.2674
- 319 9. Weller M, van den Bent M, Tonn JC, et al. European Association for Neuro-Oncology (EANO)
320 guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. *Lancet*
321 *Oncol.* 2017. doi:10.1016/S1470-2045(17)30194-8

- 322 10. Boffa DJ, Rosen JE, Mallin K, et al. Using the National Cancer Database for Outcomes Research: A
323 Review. *JAMA Oncol.* 2017;3(12):1722-1728. doi:10.1001/jamaoncol.2016.6905
- 324 11. Iorgulescu JB, Torre M, Harary M, et al. The Misclassification of Diffuse Gliomas: Rates and
325 Outcomes. *Clin Cancer Res.* 2019;25(8):2656-2663. doi:10.1158/1078-0432.CCR-18-3101
- 326 12. Harary M, Kavouridis VK, Torre M, et al. Predictors and early survival outcomes of maximal
327 resection in WHO grade II 1p/19q-codeleted oligodendrogliomas. *Neuro-Oncol.* September 2019.
328 doi:10.1093/neuonc/noz168
- 329 13. Iorgulescu JB, Harary M, Zogg CK, et al. Improved Risk-Adjusted Survival for Melanoma Brain
330 Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort.
331 *Cancer Immunol Res.* July 2018. doi:10.1158/2326-6066.CIR-18-0067
- 332 14. Ruff MW, Buckner JC, Johnson DR, Van Den Bent MJ, Geurts M. Neuro-oncology clinical debate:
333 Pcv or temozolomide in combination with radiation for newly diagnosed high-grade
334 oligodendroglioma. *Neuro-Oncol Pract.* 2019. doi:10.1093/nop/npy044
- 335 15. Boyle FM, Eller SL, Grossman SA. Penetration of intra-arterially administered vincristine in
336 experimental brain tumor. *Neuro-Oncol.* 2004. doi:10.1215/s1152851703000516
- 337 16. Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T. Temozolomide treatment for newly diagnosed
338 anaplastic oligodendrogliomas: A clinical efficacy trial. *J Neurooncol.* 2006. doi:10.1007/s11060-
339 005-9020-1
- 340 17. Ahluwalia MS, Xie H, Dahiya S, et al. Efficacy and patient-reported outcomes with dose-intense
341 temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a
342 phase II multicenter study. *J Neurooncol.* 2015. doi:10.1007/s11060-014-1684-y
- 343 18. Mikkelsen T, Doyle T, Anderson J, et al. Temozolomide single-agent chemotherapy for newly
344 diagnosed anaplastic oligodendroglioma. *J Neurooncol.* 2009. doi:10.1007/s11060-008-9735-x
- 345 19. Ducray F, Sierra Del Rio M, Carpentier C, et al. Up-front temozolomide in elderly patients with
346 anaplastic oligodendroglioma and oligoastrocytoma. *J Neurooncol.* 2011. doi:10.1007/s11060-010-
347 0264-z

- 348 20. Lassman AB, Iwamoto FM, Cloughesy TF, et al. International retrospective study of over 1000
349 adults with anaplastic oligodendroglial tumors. *Neuro-Oncol*. 2011. doi:10.1093/neuonc/nor040
- 350 21. Wick W, Society for the NWG (NOA) of the GC, Roth P, et al. Long-term analysis of the NOA-04
351 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or
352 temozolomide. *Neuro-Oncol*. 2016.
- 353 22. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential
354 radiochemotherapy of anaplastic glioma with Procarbazine, Lomustine, and Vincristine or
355 Temozolomide. *J Clin Oncol*. 2009. doi:10.1200/JCO.2009.23.6497
- 356 23. Yu T, Kang HC, Lim DH, et al. Pattern of care of anaplastic oligodendroglioma and
357 oligoastrocytoma in a Korean population: the Korean radiation oncology group study 13-12. *J*
358 *Neurooncol*. 2015. doi:10.1007/s11060-014-1660-6

359

360

361 **Fig 1** There is no difference in the unadjusted OS curves between single-agent TMZ (solid line) and
362 multi-agent PCV (dashed line) treatment for AOs (Cox regression p=0.42)

363

364

365

366

367 **Table 1.** Multivariable logistic regression analysis of factors associated with utilization of PCV, as
 368 compared to TMZ.

	total n had chemo	% had PCV	OR of PCV	95%CI	p- value
Age (yr)					
<40	295	13.2 %	2.01	(0.24-16.89)	0.52
40-49	281	10.7 %	0.96	(0.53-1.76)	0.90
50-59	281	10.7 %	Reference		
≥60	287	11.2 %	0.83	(0.44-1.57)	0.57
Sex					
Male	663	12.4 %	Reference		
Female	481	10.2 %	0.75	(0.49-1.17)	0.21
Charlson-Deyo comorbidity index					
0	937	11.7 %	Reference		
1	138	13.0 %	1.22	(0.65-2.28)	0.54
2+	69	4.4 %	0.26	(0.06-1.11)	0.07
Race/Ethnicity					
White, non-Hispanic	954	10.7 %	Reference		
Black, non-Hispanic	43	9.3 %	0.83	(0.27-2.49)	0.74
Asian/Pacific islander	40	12.5 %	0.97	(0.32-2.96)	0.95
Hispanic	83	22.9 %	1.56	(0.79-3.06)	0.20
Year of diagnosis			1.38	(1.22-1.56)	<0.001
Primary payor status					
Uninsured	43	18.6 %	Reference		
Private insurance	777	10.8 %	0.38	(0.15-0.97)	0.04
Medicare/Medicaid/Other governmental	309	12.0 %	0.46	(0.17-1.26)	0.13
Cancer hospital type					
Academic/NCI-designated program	525	11.4 %	Reference		
Community program	216	9.7 %	0.58	(0.30-1.12)	0.11
Integrated network program	108	10.2 %	0.77	(0.35-1.69)	0.52
Suppressed due to age<40*	295	13.2 %	collinear with age<40		
Hospital location (US Census Division)					
New England (CT, MA, ME, NH, RI, VT)	50	4.0 %	0.91	(0.07-11.19)	0.94
Middle Atlantic (NJ, NY, PA)	161	13.7 %	3.91	(0.47-32.55)	0.21
S. Atlantic (DC, DE, FL, GA, MD, NC, SC, VA, WV)	133	11.3 %	3.06	(0.36-26.11)	0.31
E. N. Central (IL, IN, MI, OH, WI)	146	6.9 %	1.40	(0.16-12.47)	0.77
E. S. Central (AL, KY, MS, TN)	36	11.1 %	Reference		
W. N. Central (IA, KS, MN, MO, ND, NE, SD)	97	11.3 %	4.09	(0.47-35.28)	0.20
W. S. Central (AR, LA, OK, TX)	47	8.5 %	1.73	(0.17-17.98)	0.65
Mountain (AZ, CO, ID, MT, NM, NV, UT, WY)	61	13.1 %	5.29	(0.57-49.32)	0.14
Pacific (AK, CA, HI, OR, WA)	118	13.6 %	2.94	(0.35-24.90)	0.32

TMZ vs PCV for WHO grade III Oligodendroglioma 17

Suppressed due to age<40*	295	13.2 %	collinear with age<40		
Extent of resection					
Biopsy-only	203	8.9 %	Reference		
Subtotal resection	335	11.9 %	1.20	(0.64-2.26)	0.57
Gross total resection	438	11.9 %	1.24	(0.67-2.26)	0.50
Radiotherapy					
No	167	12.0 %	Reference		
Yes	977	11.4 %	0.64	(0.36-1.16)	0.14
Tumor size, greatest dimension (cm)					
≤2.0	46	15.2 %	2.10	(0.76-5.82)	0.15
2.1-4.0	203	11.8 %	Reference		
4.1-6.0	343	11.1 %	0.86	(0.45-1.64)	0.65
>6.0	301	11.3 %	1.02	(0.53-1.95)	0.96
n/a	251	11.2 %	0.97	(0.49-1.91)	0.93

369 Abbreviations: Odds ratio (OR); confidence interval (CI); temozolomide (TMZ); procarbazine, lomustine,
 370 and vincristine (PCV). *To ensure de-identification, the NCDB excludes cancer hospital type and location
 371 data for patients <40-years-old, thus these groups are collinear with the <40-year-old age group in
 372 multivariable regression.

373

374

375

376

377

378

379

380

381

382

383

384

385


386

387 **Table 2.** Multivariable Cox regression analysis of OS in AOs.

	HR	95%CI	p-value
Chemotherapy			
None	Reference		
TMZ	0.51	(0.38-0.68)	<0.001
PCV	0.39	(0.23-0.65)	<0.001
Age (yr)			
<40	0.84	(0.54-1.29)	0.42
40-49	Reference		
50-59	2.52	(1.76-3.62)	<0.001
60+	4.19	(2.96-5.93)	<0.001
Extent of resection			
Biopsy-only	Reference		
Subtotal resection	0.58	(0.44-0.77)	<0.001
Gross total resection	0.60	(0.46-0.78)	<0.001
Radiotherapy			
Yes (ref no)	1.27	(0.95-1.69)	0.11

388 Abbreviations: Hazard ratio (HR); confidence interval (CI); temozolomide (TMZ); procarbazine,

389 lomustine, and vincristine (PCV).



Number at risk		Overall survival (mos)						
		0	12	24	36	48	60	72
No chemo	176	176	98	73	53	35	22	14
TMZ	853	853	674	511	375	250	145	73
PCV	92	92	83	56	33	17	7	5